Sagimet Biosciences SGMT 深 滬
等待開盤 08-27 09:30:00 美东时间
7.07
-0.010
-0.14%
華盛通- 最 高7.2533
- 今 開7.12
- 成交量 25.15万股
- 最 低 6.97
- 昨 收 7.08
- 總市值 2.28亿
- 52周最高 11.41
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.73
- 委 比 2.96%
- 總股本 3219.53万
- 歷史最高 20.71
- 量 比 0.37
- 振 幅 4.00%
- 歷史最低 1.73
- 每 手 1
- 風險率 2.18%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
Sagimet Biosciences announced that its management will participate in two upcoming investor conferences: the Cantor Global Healthcare Conference on September 3, 2025, and the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025. A webcast of the Cantor fireside chat will be available on Sagimet's website. Sagimet is developing FASN inhibitors targeting metabolic and fibrotic pathways, with its lead candidate denifanstat s...
08-26 11:00
Sagimet Biosciences Q2 EPS $(0.32) Beats $(0.53) Estimate
Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.53) by 39.74 percent. This is a 28 percent decrease over losses of $(0.25) per share from
08-13 19:35
Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Sagimet Biosciences reported positive Phase 3 results for denifanstat in moderate to severe acne in China, with all primary and secondary endpoints met. The company also initiated a Phase 1 trial for TVB-3567, a new FASN inhibitor for acne in the U.S. Additionally, plans for a Phase 1 trial evaluating the combination of denifanstat and resmetirom were announced. Financially, the company ended June 2025 with $135.5 million in cash, while net loss ...
08-13 11:30
Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference
Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company, announced that its management will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025. The event will be webcast and available for replay for 90 days. Sagimet focuses on developing novel fatty acid synthase (FASN) inhibitors targeting metabolic and fibrotic pathways. Its lead drug, denifanstat, is in developme...
08-05 11:00
Canaccord Genuity Initiates Coverage On Sagimet Biosciences with Buy Rating, Announces Price Target of $28
Canaccord Genuity analyst Edward Nash initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Buy rating and announces Price Target of $28.
07-24 18:19
美股牛股 | 乌龙制药暴涨近52%！CureVac升近38%，获BioNTech以12.5亿美元收购
乌龙制药暴涨近52%！研发泌尿系统治疗新药取得突破性进展；CureVac隔夜升近38%，获BioNTech以12.5亿美元收购>>
06-13 19:33
Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025
Sagimet Biosciences will host a virtual KOL event on June 16, 2025, featuring Neal Bhatia, MD, to discuss Phase 3 trial results of denifanstat for moderate to severe acne vulgaris in China. Denifanstat, a once-daily oral FASN inhibitor, met all endpoints versus placebo and was well-tolerated, highlighting FASN inhibition as a novel acne treatment mechanism. Sagimet is also advancing TVB-3567, a second oral FASN inhibitor, into Phase 1 trials for ...
06-09 11:00
美股牛股 | 稳定币巨头Circle上市首日受热捧，飙涨168.5%；科技股Nebius Group涨超17%
稳定币巨头Circle上市首日受热捧，飙涨168.5%市值超180亿美元；科技股Nebius Group涨超17%，公司获10亿美元大额融资>>
06-06 19:26
Reported Earlier, Ascletis' Denifanstat, Licensed From Sagimet, Meets All Endpoints In Phase III Trial For Moderate To Severe Acne
Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated statistically significant and clinically meaningful improvement compared to placebo in all primary, key secondary, and secondary
06-04 14:36
Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis
Denifanstat, an oral FASN inhibitor, met all primary and secondary endpoints in a Phase 3 trial for moderate to severe acne, demonstrating significant reductions in lesion counts and inflammation. It was well-tolerated with no serious adverse events. Sagimet Biosciences has initiated a Phase 1 trial for another FASN inhibitor, TVB-3567, targeting acne in the U.S. These results highlight FASN inhibition as a novel and promising approach for treati...
06-04 09:00
